Ocular Therapeutix, Inc.

NasdaqGM:OCUL Stock Report

Market Cap: US$1.3b

Ocular Therapeutix Future Growth

Future criteria checks 2/6

Ocular Therapeutix is forecast to grow earnings and revenue by 31.3% and 46.2% per annum respectively while EPS is expected to grow by 30.9% per annum.

Key information

31.3%

Earnings growth rate

30.9%

EPS growth rate

Pharmaceuticals earnings growth20.0%
Revenue growth rate46.2%
Future return on equityn/a
Analyst coverage

Good

Last updated14 Jan 2025

Recent future growth updates

Earnings Update: Ocular Therapeutix, Inc. (NASDAQ:OCUL) Just Reported Its Second-Quarter Results And Analysts Are Updating Their Forecasts

Aug 10
Earnings Update: Ocular Therapeutix, Inc. (NASDAQ:OCUL) Just Reported Its Second-Quarter Results And Analysts Are Updating Their Forecasts

Recent updates

Is Ocular Therapeutix (NASDAQ:OCUL) Weighed On By Its Debt Load?

Oct 16
Is Ocular Therapeutix (NASDAQ:OCUL) Weighed On By Its Debt Load?

Ocular Therapeutix: Focus On Axpaxli's Path To Market In Wet-AMD And Implications To Investors

Oct 11

Earnings Update: Ocular Therapeutix, Inc. (NASDAQ:OCUL) Just Reported Its Second-Quarter Results And Analysts Are Updating Their Forecasts

Aug 10
Earnings Update: Ocular Therapeutix, Inc. (NASDAQ:OCUL) Just Reported Its Second-Quarter Results And Analysts Are Updating Their Forecasts

Ocular Therapeutix: A Speculative Investment For Risk-Tolerant Investors

Jul 23

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Stocks Shoot Up 41% But Its P/S Still Looks Reasonable

Jul 15
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Stocks Shoot Up 41% But Its P/S Still Looks Reasonable

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Could Be 45% Below Their Intrinsic Value Estimate

Jun 05
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Could Be 45% Below Their Intrinsic Value Estimate

Ocular Therapeutix: Unveiling Pipeline Progress (AXPAXLI, PAXTRAVA) And Q1 Results

Jun 01

Ocular Therapeutics' Impressive Surge: A Strategic Insight

Mar 19

Ocular Therapeutix: Diabetic Retinopathy Data Q2 2024 And Wet AMD Advancement

Feb 11

Ocular Therapeutix Vies With Gene Therapies, Not Just Eylea, For Wet AMD

Jan 10

Optimistic Investors Push Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Up 31% But Growth Is Lacking

Jan 09
Optimistic Investors Push Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Up 31% But Growth Is Lacking

Is Ocular Therapeutix (NASDAQ:OCUL) Using Too Much Debt?

Oct 15
Is Ocular Therapeutix (NASDAQ:OCUL) Using Too Much Debt?

Is Ocular Therapeutix (NASDAQ:OCUL) Weighed On By Its Debt Load?

Jun 30
Is Ocular Therapeutix (NASDAQ:OCUL) Weighed On By Its Debt Load?

Analysts Just Slashed Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) EPS Numbers

Mar 08
Analysts Just Slashed Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) EPS Numbers

Is Ocular Therapeutix (NASDAQ:OCUL) Using Debt In A Risky Way?

Feb 11
Is Ocular Therapeutix (NASDAQ:OCUL) Using Debt In A Risky Way?

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Analysts Are More Bearish Than They Used To Be

Nov 16
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Analysts Are More Bearish Than They Used To Be

Earnings and Revenue Growth Forecasts

NasdaqGM:OCUL - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2027157-1709-1595
12/31/202676-204-106-1735
12/31/202572-179-142-1589
12/31/202464-188-146-1339
9/30/202461-174-119-118N/A
6/30/202461-138-91-89N/A
3/31/202460-115-87-84N/A
12/31/202358-81-76-70N/A
9/30/202358-67-73-65N/A
6/30/202355-91-78-70N/A
3/31/202352-89-68-61N/A
12/31/202251-71-63-60N/A
9/30/202250-59-60-58N/A
6/30/202250-33-59-58N/A
3/31/202249-22-68-67N/A
12/31/202144-7-67-66N/A
9/30/202139-88-57-57N/A
6/30/202132-103-58-57N/A
3/31/202122-131-53-52N/A
12/31/202017-156-54-54N/A
9/30/202012-96-68-67N/A
6/30/20207-103-74-73N/A
3/31/20206-91-79-77N/A
12/31/20194-86-80-78N/A
9/30/20192-78-74-72N/A
6/30/20192-74-65-63N/A
3/31/20192-63-58-56N/A
12/31/20182-60-51-49N/A
9/30/20182-56-48-46N/A
6/30/20182-56N/A-49N/A
3/31/20182-61N/A-48N/A
12/31/20172-63N/A-50N/A
9/30/20172-63N/A-48N/A
6/30/20172-57N/A-41N/A
3/31/20172-50N/A-39N/A
12/31/20162-45N/A-34N/A
9/30/20162-43N/A-35N/A
6/30/20162-44N/A-37N/A
3/31/20162-43N/A-36N/A
12/31/20152-40N/A-34N/A
9/30/20152-37N/A-31N/A
6/30/20152-33N/A-27N/A
3/31/20151-29N/A-23N/A
12/31/20141-29N/A-20N/A
9/30/20140-24N/A-18N/A
6/30/20140-20N/A-15N/A
3/31/20140-17N/A-13N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: OCUL is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: OCUL is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: OCUL is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: OCUL's revenue (46.2% per year) is forecast to grow faster than the US market (9% per year).

High Growth Revenue: OCUL's revenue (46.2% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if OCUL's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/23 23:46
End of Day Share Price 2025/01/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Ocular Therapeutix, Inc. is covered by 21 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Colleen KusyBaird
Anita DushyanthBerenberg
Tazeen AhmadBofA Global Research